Skip to content

Efficacy and Safety of Low-Dose Electroconvulsive Therapy in Geriatric Depressive Disorders and Efficacy Prediction Study Based on Brain Imaging Features

Efficacy and Safety of Low-Dose Electroconvulsive Therapy in Geriatric Depressive Disorders and Efficacy Prediction Study Based on Brain Imaging Features

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129671
Enrollment
Unknown
Registered
2026-08-07
Start date
2026-10-01
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

low dose ECT group:low dose ECT
standard dose ECT group:standard dose ECT
External Control Group:antidepressant

Sponsors

Beijing Huilongguan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Meets the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnostic criteria for a depressive episode; 2.Aged 60–85 years; 3.Hamilton Depression Rating Scale (17-item, HAMD-17) score > 17; 4.The patient and their family members voluntarily participate and sign the informed consent form; 5.No contraindications for electroconvulsive therapy (ECT); 6.No color blindness or physical disabilities that would interfere with cognitive function testing; 7.Educational level of primary school or above.

Exclusion criteria

Exclusion criteria: 1.Other mental disorders meeting the DSM-5 diagnostic criteria, such as dementia, schizophrenia, etc. 2.Definite history of epileptic seizures or delirium tremens; 3.History of dependence on stimulants, narcotics, or sedative-hypnotics; 4.Severe or unstable medical conditions; 5.Concurrent use of other medications that may affect efficacy evaluation, such as benzodiazepines, neuroleptics, etc. 6.Contraindications for MRI scanning; 7.Receipt of other physical or psychological treatments affecting cognitive function within the past 6 months.

Design outcomes

Secondary

MeasureTime frame
Repeatable Battery for the Assessment of Neuropsychological Status;Charlson Comorbidity Index;Clinical Global Impression Score;Hamilton Anxiety Scale Score;subject memory;Brain structure and functional MRI indicators;Self-rating Idea of Suicide Scale Score;Incidence of adverse events and reactions;Chinese version of the Mini-Mental State Examination (MMSE) Score;Montreal Cognitive Assessment Score;

Primary

MeasureTime frame
17-item Hamilton Depression Rating Scale;

Countries

China

Contacts

Public ContactCai Haipeng

Beijing Huilongguan Hospital, Capital Medical University

99sspp@163.com+86 10 83024319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026